Will anyone tell Dr Cashman to submit PMN310 to Linse?PMN has no money to run a trial.
No large pharmaceutical company will give PMN money for a joint venture.
So how can PMN get some real attention for PMN310? Easy-- have Dr Cashman give a sample to the team headed by Linse, asking that the same testing be done that was done on the other four samples.
You can then learn pretty quickly if PMN310 is really better than Aducanumab, without needing a trial.
Full disclosure (once more)-- I own no PMN shares. The Amyloid Hypothesis does not provide the true etiology of Alzheimer's. And oligomers are still part of the Amyloid Hypothesis, as Dennis Selkoe and the other really big boys state that oligomers come from the amyloid plaques.
I occasionally check in and read this board only for entertainment purposes.